Files in this item
Characterisation of ferritin–lymphocyte ratio in COVID-19
Item metadata
dc.contributor.author | Liu, Alexander | |
dc.contributor.author | Hammond, Robert | |
dc.contributor.author | Chan, Kenneth | |
dc.contributor.author | Chukwuenweniwe, Chukwugozie | |
dc.contributor.author | Johnson, Rebecca | |
dc.contributor.author | Khair, Duaa | |
dc.contributor.author | Duck, Eleanor | |
dc.contributor.author | Olubodun, Oluwaseun | |
dc.contributor.author | Barwick, Kristian | |
dc.contributor.author | Banya, Winston | |
dc.contributor.author | Stirrup, James | |
dc.contributor.author | Donnelly, Peter D. | |
dc.contributor.author | Kaski, Juan C. | |
dc.contributor.author | Coates, Anthony R. M. | |
dc.date.accessioned | 2023-10-18T10:30:07Z | |
dc.date.available | 2023-10-18T10:30:07Z | |
dc.date.issued | 2023-10-18 | |
dc.identifier | 294665181 | |
dc.identifier | 065c45c6-822a-48ae-ac8f-76c0192bf122 | |
dc.identifier | 85175165964 | |
dc.identifier | 001098245200001 | |
dc.identifier | 37893192 | |
dc.identifier.citation | Liu , A , Hammond , R , Chan , K , Chukwuenweniwe , C , Johnson , R , Khair , D , Duck , E , Olubodun , O , Barwick , K , Banya , W , Stirrup , J , Donnelly , P D , Kaski , J C & Coates , A R M 2023 , ' Characterisation of ferritin–lymphocyte ratio in COVID-19 ' , Biomedicines , vol. 11 , no. 10 , 2819 . https://doi.org/10.3390/biomedicines11102819 | en |
dc.identifier.issn | 2227-9059 | |
dc.identifier.other | RIS: urn:77F7F449793B26DA7F66E35238BFC41C | |
dc.identifier.other | ORCID: /0000-0003-3664-3641/work/157140947 | |
dc.identifier.uri | https://hdl.handle.net/10023/28542 | |
dc.description.abstract | Introduction: The ferritin–lymphocyte ratio (FLR) is a novel inflammatory biomarker for the assessment of acute COVID-19 patients. However, the prognostic value of FLR for predicting adverse clinical outcomes in COVID-19 remains unclear, which hinders its clinical translation. Methods: We characterised the prognostic value of FLR in COVID-19 patients, as compared to established inflammatory markers. Results: In 217 study patients (69 years [IQR: 55–82]; 60% males), FLR was weakly correlated with CRP (R = 0.108, p = 0.115) and white cell count (R = −0.144; p = 0.034). On ROC analysis, an FLR cut-off of 286 achieved a sensitivity of 86% and a specificity of 30% for predicting inpatient mortality (AUC 0.60, 95% CI: 0.53–0.67). The negative predictive values of FLR for ruling out mortality, non-invasive ventilation requirement and critical illness (intubation and/or ICU admission) were 86%, 85% and 93%, respectively. FLR performed similarly to CRP (AUC 0.60 vs. 0.64; p = 0.375) for predicting mortality, but worse than CRP for predicting non-fatal outcomes (all p < 0.05). On Kaplan–Meier analysis, COVID-19 patients with FLR values > 286 had worse inpatient survival than patients with FLR ≤ 286, p = 0.041. Conclusions: FLR has prognostic value in COVID-19 patients, and appears unrelated to other inflammatory markers such as CRP and WCC. FLR exhibits high sensitivity and negative predictive values for adverse clinical outcomes in COVID-19, and may be a good “rule-out” test. Further work is needed to improve the sensitivity of FLR and validate its role in prospective studies for guiding clinical management. | |
dc.format.extent | 12 | |
dc.format.extent | 2407728 | |
dc.language.iso | eng | |
dc.relation.ispartof | Biomedicines | en |
dc.subject | Coronavirus disease 19 | en |
dc.subject | Ferritin–lymphocyte ratio | en |
dc.subject | Inflammatory biomarkers | en |
dc.subject | Risk stratification | en |
dc.subject | C-reactive protein | en |
dc.subject | White cell count | en |
dc.subject | COVID-19 | en |
dc.subject | QR355 Virology | en |
dc.subject | RM Therapeutics. Pharmacology | en |
dc.subject | E-DAS | en |
dc.subject.lcc | QR355 | en |
dc.subject.lcc | RM | en |
dc.title | Characterisation of ferritin–lymphocyte ratio in COVID-19 | en |
dc.type | Journal article | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.contributor.institution | University of St Andrews. Infection and Global Health Division | en |
dc.identifier.doi | 10.3390/biomedicines11102819 | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.